Systemic gene delivery systems are needed for therapeutic application to organs that are inaccessible by percutaneous injection. Currently, the main objective is the development of a stable and non-toxic vector that can encapsulate and deliver foreign genetic material to target cells. To this end, DNA, complexed with cationic lipids i.e DOTAP/DOPE, was encapsulated into lipid nanocapsules (LNCs) leading to the formation of stable nanocarriers (DNA LNCs) with a size inferior to 130nm. Amphiphilic and flexible poly (ethylene glycol) (PEG) polymer coatings [PEG lipid derivative (DSPE-mPEG 2000 ) or
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-Introduction
For the treatment of unreachable organs and disseminated or metastatic cancer, it is now essential to develop intravenous forms of gene therapy. However, systemic targeting remains a real challenge. Synthetic vectors based on the use of cationic lipids or polymers associated to DNA appear to have promising potential, given the safety problems encountered with viral vectors. Nevertheless, the systemic injection of these synthetic carriers usually results in a toxic response linked to their strong positive charge, incompatible with clinical applications [1] .
Furthermore, when injected intravenously, colloidal carriers are rapidly cleared by the mononuclear phagocyte system (MPS) mainly represented by Kupffer cells in the liver and spleen macrophages. The recognition of the carriers by macrophages usually occurs through specific recognition by cellular receptors specific for plasma proteins that have been adsorbed at the vector surface. Among them, the C3 protein of the complement system plays a major role in the immune system's recognition of foreign particles [2] . The concept of modifying the surface of vectors has therefore been applied in order to decrease the opsonisation process and the specific or non-specific recognition by MPS and blood components [3] .
Heurtault et al. [4] developed lipid nanocapsules synthesised by a solvent-free method and covered by PEG 660 at high density, leading to really weak complement activation and low macrophage uptake [3, 5] . In a previous work, the formulation of these nanocapsules was adapted to obtain DNA nanocapsules (DNA LNCs) [6] . Thanks to the use of oleic Plurol ® instead of Lipoid ® in their formulation, the lipid core allowed the entrapment of plasmid DNA molecules via the formation of lipoplexes (cationic liposomes of DOTAP:DOPE complexed with plasmid DNA). DNA LNCs were small (117 ± 10nm), suitable for an intravenous injection, but in vivo stability and blood half-life remained low and were ill-adapted to efficient in vivo transfection [6] .
To allow an extended circulation time, and consequently a higher tumor selectivity by passive accumulation through the EPR (enhanced permeability and retention) effect [7] , we chose to modify the surface of our gene delivery systems, by inserting longer PEG chains at the surface of DNA LNCs between the already-existing, dense PEG 660 chains. This was carried out through the use of two kinds of amphiphilic and flexible polymers. The first one was F108 block copolymer, consisting of ethylene oxide (EO) and propylene oxide (PO) blocks arranged in a triblock structure (EO 132 -PO 50 -EO 132 ). This kind of amphiphilic polymer recently demonstrated great promise for the delivery of pDNA, thanks to its proven in vivo transfection efficiency [8] [9] [10] [11] . The second one was a lipid PEG derivative, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (DSPEmPEG 2000 ). The ability of the different particles to escape complement activation and uptake by THP-1 macrophages was investigated. Then the long-circulating properties of these particles in vivo after intravenous injection in mice and their tumor accumulation ability by NIR fluorescence imaging system were evaluated. In parallel, blood samples were harvested to measure the hepatotoxic impact of the different formulations before and after injection.
-Materials and methods
-Preparation of the nano-colloids
-Liposomes
DOTAP (1,2-DiOleoyl-3-TrimethylAmmonium-Propane) and DOPE (1,2-DiOleyl-sn-glycero-3-PhosphoEthanolamine) (Avanti Polar Lipids, Inc, Alabaster, USA) were first dissolved in chloroform (Sigma, Saint-Quentin Fallavier, France) and then dried by an evaporation process under vacuum.
The formed lipid film was hydrated with deionized water. Then liposomes were sonicated for 20 minutes. Lipoplexes were prepared by mixing DOTAP/DOPE (1/1, M/M) liposomes with 660µg of luciferase-encoding plasmid [10] (pgWIZ-luciferase amplified and research grade purified by GENEART, Regensburg, Germany) at a charge ratio of 5 (+/-) in 150mM NaCl.
-DNA-loaded lipid nanocapsules (DNA LNCs)
The formulation of LNCs was based on a phase-inversion process described by Heurtault et al. [12] . % of Solutol ® (w/w), 9.9 % of Labrafac ® (w/w), 78.9 % of water (w/w) and 1.4 % of NaCl, were mixed together under magnetic stirring. DNA LNCs were synthesized as already described [6] . Fluorescent lipid nanocapsules (DiI or DiD empty LNCs and DiI or DiD DNA LNCs) were obtained by a previouslydescribed method [13] . Briefly, 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI, emission wavelength (em.) = 549nm; excitation wavelength (exc.) = 565nm) or 1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine perchlorate (DiD, em.= 644nm; exc.= 665nm) (Invitrogen, Cergy Pontoise, France) was dissolved in acetone at 6 0 / 00 (w/w) and the resulting DiI or DiD stock solution was incorporated in Labrafac ® (1:10 (w/w)). Finally, acetone was evaporated before use. . This purification step providing a desalting effect, the salt concentration of the suspension was therefore adapted to obtain a physiologic concentration of NaCl (150mM). Pre-formed LNCs and DSPE-mPEG 2000 or F108 micelles were co-incubated for 4h at 30°C. The mixture was vortexed every 15 minutes and then quenched in an ice bath for 1 minute. To provide controls, the same thermal treatments were applied to LNC suspensions without polymers.
-Preparation of coated nanocapsules by post-insertion
-Polymethyl methacrylate nanoparticles (PMMA NP)
Polymethyl methacrylate (PMMA) nanoparticles were synthesized by the polymerisation of methyl methacrylate (MMA, Merck, Hohenbrunn, Germany) as described previously [14] . To obtain fluorescent PMMA NPs, the pre-formed PMMA particles were allowed to swell in methanol during an incubation period of 2h at room temperature with DiI dissolved in acetone. The water-insoluble DiI diffused into the PMMA nanoparticles and was entrapped when the solvent was removed through the evaporation process, for 30min. at 70°C.
-Characterisation of the nanoparticles
-Physico-chemical characteristics of coated DNA LNCs
The average hydrodynamic diameter and the polydispersity index (PI) of the LNCs were determined by dynamic light scattering (DLS) using a Malvern Zetasizer ® (Nano Series DTS 1060, Malvern Instruments S.A., Worcestershire, UK). A 1:100 dilution of the nanoparticle in deionized water was processed and size measurement was performed at 25°C (in triplicate). The measure of zeta potential was achieved on nanoparticle suspensions at 150mM NaCl diluted in deionized water at 1:100, providing a final salt concentration of 1,5mM.
-DNA stability study
The stability of nanocapsule suspensions during storage at 4°C was assessed by measuring the size distribution. The stability was also tested after centrifugation at 15,000g at room temperature for 20min in order to visualize any demixing among the components. were grown in suspension in a humidifier-incubator (5% CO 2 ) at 37°C in ATCC suggested medium.
Cells were cultured in the same medium with 200mM Phorbol 12-myristate 13-acetate (PMA, Sigma, Saint-Quentin Fallavier, France) for 24h to allow adherence and differentiation [15] . The medium was then aspired (to eliminate non-adhered cells) and the cells were subsequently incubated in a new medium for an additional 24h prior to uptake studies. Cells were harvested and counted using Trypan blue exclusion assay with a haemacytometer. Cells (0.6 x 10 6 /ml) were plated on sterile, 24-well cell culture clusters, and then allowed to grow for 24h at 37°C.
-Cytotoxicity assay
The 24-well plates were exposed to different suspensions (free DNA, free lipoplexes, empty LNCs, and DNA LNCs, at a DNA concentration equivalent to the DNA LNCs one, excepted for empty LNCs). Nanoparticles were prepared at a DNA concentration of 446µg/ml and 1:10 cascade dilutions were performed in culture (44.6, 4.46 and 0.446µg/ml). After 48h of exposure, cell viability was determined by the MTT test performed in triplicate according to the procedure described by Mosmann [16] . Briefly, 40µl of MTT solution at 5mg/ml in phosphate-buffered saline (PBS) 1X was added to each well, and then the plates were incubated at 37°C fo r 4h. The medium was removed and 200µl of 0.06N acid-isopropanol was added to each well and mixed thoroughly to completely dissolve the dark blue crystals. The optical density was measured at 580nm using a Microplate reader Multiskan Ascent (Thermo Fisher Scientific, Cergy-Pontoise, France).
-Internalization study by cellular imaging
Cells were incubated with a series of 2-fold dilutions of Dil-labelled LNC suspensions starting from 1/100. After 20min or 24h, macrophages were stained with Syto60 (Invitrogen, Cergy Pontoise, France). Confocal images were recorded on an automated fluorescent confocal microscope Opera TM (PerkinElmer) using a 20X-water objective (NA 0.70). Dil-labelled LNCs were detected using a 532nm laser coupled with a 565/50nm detection filter (green channel) and cells labelled with Syto 60 were identified with a 635nm laser coupled with a 690/40nm detection filter (red channel). Four independent pictures were taken for each plate well and each image was then processed in order to quantify the number of green LNCs and cells.
-Complement activation study
Complement consumption was assessed in normal human serum (NHS) (provided by the Etablissement Francais du Sang, CHU, Angers, France) by measuring the residual haemolytic capacity of the complement system after contact with the different particles [2] . The technique consisted in determining the amount of serum able to lyse 50% of a fixed number of sensitized sheep erythrocytes with rabbit anti-sheep erythrocyte antibodies (CH50), according to the procedure described elsewhere [5] . Complement activation was expressed as a function of the surface area in order to compare particles with different mean diameters. Nanoparticle surface areas were calculated as described elsewhere [14] , using the equation: S = n4πr 2 and V = n(4/3)(πr . All experiments were performed in triplicate and a t-test of non-matched samples was used to test for the statistical significance of the results.
-In vivo hepato-toxicity study after IV injection
Blood samples (~200 µL) were collected from the saphenous vein of the mice on a heparin tube before and 24 h after administration. Tubes were then centrifuged at 10000×g for 2 min at +4 °C and plasma were harvested to measure the activity of the ALAT (alanine amino transferase) and ASAT (aspartate aminotransferase) enzymes. For ALAT measurements, two solutions were needed (S1 = Tris buffer at pH 7. 
-In vivo fluorescence imaging
Tumor bearing mice were prepared by injecting subcutaneously a suspension of 1 (Berthold France, Thoiry, France). As DiD fluorescent tag was used to localize the nanoparticles, the 590nm excitation filter and the 655nm emission filter were selected. In parallel, the light beam was kept constant for each fluorescent measurement, which was ideal with the ringlight epi illumination. If the ringlight was always set at the same height, the excitation energy on the sample would always be the same.
Each mouse was anesthetized with a 4% air-isofluran blend. Once laid in the acquisition chamber, the anesthesia of the mice was maintained with a 2% air-isofluran mixture all along the experiment. With the BFI system, the fluorescent acquisition time was 2 sec and the fluorescent signal was then overlaid on a picture of the mice.
CCD camera collected light coming out from the skin of the animal without any a priori information regarding the deepness of the sources. However, excitation and emission photons employed in our experiments have a mean path before absorption of 1-2 cm, and this property depends on the optical characteristic of tissues themselves. Thus, since the photons can pass up to 2 cm through the animal body, sources located up to 2 cm below the skin can be visualized. However, in order to unambiguously localize the fluorescent dye accumulated in specific anatomical areas, a much more detailed study should be performed.
-Results
-Preparation of stealth DNA LNCs and physicochemical characterization of the different coatings
The physico-chemical properties (Table 1 ) and the DNA encapsulation ability (Figure 1 ) of DNA LNCs were examined before and after the post-insertion of DSPE-mPEG 2000 or F108. We used DSPE-mPEG 2000 concentrations from 2 to 10mM, and F108 concentrations from 1 to 3mM. The high molecular weight of F108 (14,600Da) did not allow us to associate more than 3mM of F108 at the LNC surface. Above this concentration demixing was observed, indicating an excess of F108. A higher density of DSPE-mPEG 2000 chains was therefore possible to obtain at the LNC surface.
Compared to empty LNCs (48 ± 4nm), the lipoplexe-loaded LNCs (DNA LNCs) demonstrated a significant increase in size (117 ± 10nm) and zeta potential measured in a final concentration of 1,5
mM NaCl (+30 ± 2mV versus -14 ± 1mV for empty LNCs) ( Table 1 ). The mean size obtained after the post-insertion of DSPE-mPEG 2000 was 131 ± 10, 139 ± 19 and 142 ± 20nm for 2, 5, 10mM
respectively. When adding F108 block copolymers, the sizes were weakly increased with 129 ± 2, 129 ± 4, and 132 ± 3 for 1, 2, 3mM respectively. In all cases, size increase was between 130 and 142nm, whatever the concentration, without significant differences. The zeta potential values decreased progressively from +30mV for DNA LNCs to -41mV with increasing concentrations of DSPEmPEG 2000 . DNA LNC zeta potentials decreased more weakly in the case of F108 incorporation, i.e.
+14, +17 and +22mV for 1, 2 and 3mM, respectively.
Agarose gel electrophoresis experiments showed that DNA molecules did not migrate after the nanocapsule formulation process. By contrast, incubation of nanocapsules with Triton ® led to the release of DNA molecules that migrated into the gel (Figure 1 ). These results clearly indicate that the addition of polymers at the surface of DNA LNCs does not disturb encapsulation (lanes 4 to 15) and that DNA molecules remain well encapsulated inside nanoparticles. F108 at a concentration of 3mM showed an even higher activation level than non-coated DNA LNCs.
-Macrophage uptake
-Blood distribution of LNCs in Swiss mice
With the goal of following the blood half-lives of LNCs in Swiss mice, we used fluorescentlabeled LNCs injected in the tail vein at a DNA concentration of 3.35mg/kg of animal weight.
Thereafter blood samples were collected from one minute (expressed as the 100% of the injected dose) to 24 hours, and the plasma was dosed for its fluorescent content. As seen in Figure 5 , DNA LNCs were quite rapidly cleared from the circulation with 50% of fluorescence detected in the plasma at 0.3h post injection (versus 0.7h for empty LNCs). DNA LNCs coated with 2mM DSPE-mPEG 2000 exhibited a t 1/2 of distribution increase from 1.4h to 1.6h (Table 2) , and the AUC raised from 194 to 325% of the injected dose per hour (Table 2) . When adding 5mM and 10mM of DSPE-mPEG 2000 , respectively, to the surface of DNA LNCs, 47% and 56% of the injected dose was still circulating 4 hours after injection ( Figure 5A ), to reach a t 1/2 of distribution of 7.1 hours with 10mM of DSPE-mPEG 2000 . The AUCs of these formulations were 539 and 773% of the injected dose per hour respectively ( 
-Tumor accumulation of coated DNA LNCs
To estimate time dependant excretion profile and tumor accumulation of the polymer coated LNCs exposing the greatest residence time in blood stream (10mM DSPE-mPEG 2000 ), these suspensions were intravenously injected in the tail vein of tumor bearing mice and compared to non coated DNA LNCs. Tissue distribution was evaluated thanks to NIR biofluorescence imaging (BFI)
system. First of all, the early fluorescence signals were much more intense after injection of coated DNA LNCs than after the administration of uncoated particles. When regarding non covered DNA LNCs, the fluorescence intensity increased in the liver area from 3h after injection up to 24h, whereas no accumulation in this anatomical area was observed with 10mM DSPE-mPEG 2000 -coated DNA LNCs at any time ( Figure 6 ). In parallel, a fluorescence emission was observed 3h, 5h, 24h, and 48h after DNA LNCs injection on the kidney area, which could therefore let think to an elimination of DNA LNCs via urinary system. At 24h and 48h after injection, DSPE-mPEG 2000 -covered DNA LNCs displayed stronger fluorescence intensity in the tumor and in its vicinity, compared to non coated DNA LNCs.
-Discussion
The formulation process led to the creation of empty LNCs or DNA LNCs with very different size and surface charge properties (Table 1) PEG lipid derivatives DSPE-mPEG 2000 and block copolymers F108 were associated to preformed nanocapsules by the post-insertion method, usually used to create stealth liposomes, and recently applied to LNCs [18, 19] . The centrifugation (15,000g, 20min ., 20°C) of coated DNA LNCs revealed a good level of stability of all the particles. Nevertheless, high concentrations of F108 (>3mM) led to demixing (data not shown), whereas this was never observed with DSPE-mPEG 2000 at any concentration. This could be explained by steric overcrowding, due to the high molecular weight of F108 chains (14,600Da) that induced a weaker reachable density of F108 molecules at the surface of the particles (Table 3 ). The theoretical calculations of several characteristics of the coating exposed in Table 3 were based on the mean diameter measurements (A= 4πr As already described [5, 6, 14] , free lipoplexes and PMMA NP strongly activated the proteins of the complement system as assessed in vitro by the CH50 test (Figure 4 ). The high cationic and anionic charges at lipoplexe and PMMA NP surfaces respectively, govern interactions with plasmacomplement proteins via the alternative pathway and also interactions with cells membranes [22, 23] .
In comparison with empty LNCs that present no complement activation and no macrophage uptake ( Figures 3 and 4) , DNA LNCs showed weak complement activity, but more pronounced macrophage uptake ( Figure 4 ). While the coating of DNA LNCs with F108 led to the same activation as with noncoated DNA LNCs, DSPE-mPEG 2000 led to the inhibition of complement activation down to the empty LNC level. As expected, the addition of DSPE-mPEG 2000 improved macrophage escape (Figure 3 ).
The high charge of DNA LNCs (+30mV) was dissimulated thanks to the use of DSPE-mPEG 2000 polymers, to reach a still positive (+22mV) or negative (-12mV or -41mV) surface charge. These differences of zeta potentials are linked to the fact that DSPE-PEG chains can form negative dipoles that are able to diminish the surface charge proportionally to their concentration [24] . This negative charge, close to that of empty LNCs (-14mV) prevented their removal via non-specific interactions with receptors by electrostatic attraction at the macrophage surface [25, 26] , mainly observed with positive charges. By contrast, F108-coated DNA LNCs were largely taken up; this could be linked to their positive charge (+22mV) or to a dissociation of F108 copolymers and DNA LNCs which resulted in their rapid uptake by the MPS. One hypothesis is also that the PPO hydrophobic moieties present on F108 could be accessible to opsonins and consequently provide more association to cells compared to the hydrophobic moieties of DSPE-mPEG 2000 which are anchored in the nanocapsule core [18, 27] .
It is now well established that a dissociation of the PEG chains from the particles is required to interact with cell membranes [28] and, in this case, the disadvantage of F108 can become an advantage.
Indeed, DSPE-mPEG 2000 coated DNA LNCs were less efficient than F108 covered ones in in vitro
HeLa cell transfection as previously described [29] . Anyway, there is, in vivo, a need of finding equilibrium between transfection and pharmacokinetic behavior [28] .
As our final aim was to obtain long-circulating vectors for systemic gene delivery, we then investigated the plasma clearance of fluorescent LNCs in Swiss mice. It is well known that the low circulation time of free lipoplexes explains their poor efficiency for gene delivery in vivo, with only 1% detected in the blood 5min after injection in mice [30] . By contrast, DNA LNCs exposed 93% of the injected dose at the same time ( Figure 5 ).
In order to enhance their circulation time we chose to protect the DNA LNC surface with DSPE-mPEG 2000 or F108 poloxamers. The half-lives and the mean residence time for all the DSPEmPEG 2000 and F108-coated DNA LNCs were higher than for DNA LNCs However, F108 poloxamers did not efficiently improve circulation properties, probably because the surfactant is displaced on dilution in the blood and enters into competition with opsonins. This confirm that the anchorage of PEG chains in DNA LNCs is essential for prolonging the in vivo residence time [31] . By contrast, DSPEmPEG 2000-coated DNA LNCs had extended half lives, and the blood circulation time increased with the density of DSPE-mPEG 2000 chains. The distance between two PEG chains from 5 to 2.33nm (Table 3) and their density is in good agreement with other long-circulating systems such as PLA-PEG nanocapsules [31] .
The excretion profile of DNA LNCs and 10mM DSPE-mPEG 2000 Consistently with blood kinetic profiles ( Figure 5 and Table 2 ), DNA LNCs were rapidly localized in the liver and in the kidney suggesting a removal by the MPS. By contrast, DSPE-mPEG 2000 coated DNA LNCs were able to accumulate in the tumor and its neighborhood by passive targeting thanks to a sufficient circulation time in blood. The low hepatotoxic impact of these coated particles was also a positive point.
This newly formed vector can advantageously be compared to other gene therapy systems reported in the literature. Actually, as exposed in the study of Cui et al., 30 min. after tail-vein injection in mice, only 40% of the pDNA entrapped in nanoparticles synthesized from emulsion remained in the circulating blood [32] . Even the clinically relevant systemic RNAi-mediated gene silencing in nonhuman primates developed by Zimmermann et al. [33] , exposed a half-life in mice of 38 minutes.
However, the circulation time of stabilized plasmid lipid particles (SPLP) in the blood can vary from 1h to 16h, depending on the PEG lipid anchor used. Nevertheless this study also showed that the PEG lipid anchor has to be disassociated from the particle surface in order to transform the complex from a anchors (C 14 ) and a distribution t 1/2 of 2h.
-Conclusion
The DSPE-mPEG 2000 coated DNA LNCs developed here are able to circulate in the bloodstream without being degraded or captured by the cellular defense mechanisms, and to accumulate in the tumor area. One hurdle, the extracellular one, is therefore crossed, but numerous barriers still exists at the cellular level, and efforts have to be made to still improve this vector.
Nevertheless, this DNA delivery system seem to be an excellent candidate for an efficient in vivo transfection, either by the enhanced and permeability retention effect (EPR effect) [7] or by active targeting thanks to the grafting of specific molecules to the extremity of the longest PEG chains. A. B. Coloured bar on the left or upper part of the picture indicates the signal efficient of the fluorescence emission coming out from the animal. The tumor location is specified with a white arrow. 
